SMC4: A Potential Drug Target and Biomarker (G10051)

Target Name: SMC4

NCBI ID: G10051

SMC4

SMC4: A Potential Drug Target and Biomarker

Small cell lung cancer (SCLC) is a subtype of lung cancer that affects approximately 20% of all lung cancer cases. Despite advances in treatment, the survival rate for SCLC remains poor, with a five-year survival rate of only 5%. The need for new, more effective treatments has led to the exploration of potential drug targets and biomarkers. In this article, we discuss SMC4, a potential drug target and biomarker for SCLC.

SMC4: Structure and Function

SMC4 is a non-coding RNA molecule that has been identified as a potential drug target for SCLC. It is located on chromosome 6 and has been shown to play a role in cell proliferation and survival. SMC4 has been shown to promote the growth and survival of SCLC cells in both in vitro and in vivo models.

SMC4 is expressed in a variety of tissues and has been shown to be involved in the development and progression of SCLC. It has been shown to be overexpressed in SCLC and has been identified as a potential biomarker for the disease.

SMC4 as a Drug Target

SMC4 has been shown to be a good candidate for drug targeting due to its unique structure and function. It has a small size, which makes it easier to deliver to the tumor site. It also has a high localization coefficient, which means it is preferentially localized to the tumor site.

SMC4 has been shown to interact with several drug targets that are commonly used to treat SCLC, including the androgen receptor (AR), the angiogenesis factor (TGF-β), and the cell cycle regulator (p21). These drug targets are involved in various aspects of SCLC growth and progression, including cell proliferation, angiogenesis, and drug resistance.

SMC4 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as the production of angiogenesis factors and the regulation of the cell cycle.

SMC4 as a Biomarker

SMC4 has also been shown to be a potential biomarker for SCLC. It has been shown to be overexpressed in SCLC and has been used as a marker for the disease in both in vitro and in vivo models.

SMC4 has been shown to be associated with poor prognosis in SCLC patients. In a study of patients with advanced SCLC, those with high SMC4 expression had a poor prognosis, with a five-year survival rate of only 17%. This suggests that SMC4 may be a useful biomarker for identifying patients at high risk for SCLC treatment.

Conclusion

SMC4 is a potential drug target and biomarker for SCLC. Its unique structure and function make it an attractive target for drug development. SMC4 has been shown to promote the growth and survival of SCLC cells and has been identified as a potential biomarker for the disease. Further research is needed to confirm its potential as a drug target and biomarker for SCLC.

Protein Name: Structural Maintenance Of Chromosomes 4

Functions: Central component of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases

The "SMC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets